Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Capital Expenditures data on file, last reported at $265000.0 in Q2 2026.

• Quarterly Capital Expenditures fell 46.79% year-over-year to $265000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.2 million (up 16.85% YoY) and the FY2025 annual result came in at $2.4 million, up 90.28% from the prior year.
• Capital Expenditures fell to $265000.0 in Q2 2026, from $713000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $9.8 million in Q2 2022 to a low of $12000.0 in Q1 2024.
• A 5-year average of $1.5 million and a median of $538000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 5630.41% — and 2024, when it tumbled 99.43%.
• Tracing BCYC's Capital Expenditures over 5 years: stood at $1.4 million in 2022, then slumped by 96.48% to $51000.0 in 2023, then surged by 621.57% to $368000.0 in 2024, then jumped by 55.98% to $574000.0 in 2025, then sank by 53.83% to $265000.0 in 2026.
• The last three Capital Expenditures figures came in at $265000.0 (Q2 2026), $713000.0 (Q1 2026), and $574000.0 (Q4 2025), per Business Quant data.